



Clinical trial results:

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK)

Summary

EudraCT number	2018-003308-38
Trial protocol	DE FI
Global end of trial date	26 March 2021

Results information

Result version number	v2 (current)
This version publication date	04 August 2022
First version publication date	08 October 2021
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	V114-031
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03692871
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 March 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 March 2021
Global end of trial reached?	Yes
Global end of trial date	26 March 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This study was designed to evaluate the safety and tolerability of V114 and Prevnar 13™ in healthy infants. The study included both full-term infants (≥ 37 weeks gestational age) and premature infants (< 37 weeks gestational age). Premature infants were included in a Premature Infant Immunogenicity Substudy, which assessed immunogenicity and safety following administration of V114 or Prevnar 13™.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 December 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 34
Country: Number of subjects enrolled	Canada: 309
Country: Number of subjects enrolled	Finland: 221
Country: Number of subjects enrolled	Germany: 215
Country: Number of subjects enrolled	Israel: 97
Country: Number of subjects enrolled	Malaysia: 291
Country: Number of subjects enrolled	Peru: 183
Country: Number of subjects enrolled	Taiwan: 135
Country: Number of subjects enrolled	Thailand: 391
Country: Number of subjects enrolled	United States: 533
Worldwide total number of subjects	2409
EEA total number of subjects	436

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	2409
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study enrolled healthy infants. Other inclusion criteria applied.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	V114

Arm description:

Participants received a single 0.5 mL intramuscular (IM) injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).

Arm type	Experimental
Investigational medicinal product name	V114
Investigational medicinal product code	
Other name	VAXNEUVANCE™ Pneumococcal 15-valent Conjugate Vaccine
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

15-valent pneumococcal capsular polysaccharide with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose

Arm title	Prevnar 13™
------------------	-------------

Arm description:

Participants received a single 0.5 mL IM injection of Prevnar 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).

Arm type	Active comparator
Investigational medicinal product name	Prevnar 13™
Investigational medicinal product code	
Other name	Pneumococcal 13-valent Conjugate Vaccine
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

13-valent pneumococcal capsular polysaccharide with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose

Number of subjects in period 1	V114	Prevnar 13™
Started	1972	437
Completed	1847	400
Not completed	125	37
Physician decision	22	7
Protocol Deviation	1	-
Death	1	1
Withdrawal by Parent/Guardian	77	20
Lost to follow-up	24	9

Baseline characteristics

Reporting groups

Reporting group title	V114
Reporting group description:	
Participants received a single 0.5 mL intramuscular (IM) injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).	
Reporting group title	Prevnar 13™
Reporting group description:	
Participants received a single 0.5 mL IM injection of Prevnar 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).	

Reporting group values	V114	Prevnar 13™	Total
Number of subjects	1972	437	2409
Age Categorical Units: Participants			
Age Continuous Units: weeks			
arithmetic mean	8.7	8.8	
standard deviation	± 1.5	± 1.5	-
Gender Categorical Units: Participants			
Female	948	227	1175
Male	1024	210	1234
Race Units: Subjects			
American Indian or Alaska Native	64	20	84
Asian	730	152	882
Black or African American	54	19	73
Multiple	154	31	185
Native Hawaiian or Other Pacific Islander	2	1	3
White	966	214	1180
Missing	2	0	2
Ethnicity Units: Subjects			
Hispanic or Latino	293	74	367
Not Hispanic or Latino	1678	362	2040
Not Reported	1	1	2

End points

End points reporting groups

Reporting group title	V114
Reporting group description: Participants received a single 0.5 mL intramuscular (IM) injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).	
Reporting group title	Prevnam 13™
Reporting group description: Participants received a single 0.5 mL IM injection of Prevnam 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).	

Primary: Percentage of Participants with a Solicited Injection-site Adverse Event

End point title	Percentage of Participants with a Solicited Injection-site Adverse Event
End point description: An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs included injection-site erythema (redness), injection-site induration (hard lump), injection-site pain (tenderness), and injection-site swelling. The analysis population for this endpoint included all randomized participants who received at least 1 dose of study vaccination.	
End point type	Primary
End point timeframe: Up to Day 14 after each study vaccination	

End point values	V114	Prevnam 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1965	433		
Units: Percentage of participants				
number (not applicable)				
Injection site erythema	43.9	36.0		
Injection site induration	25.3	25.6		
Injection site pain	42.9	36.5		
Injection site swelling	27.9	23.3		

Statistical analyses

Statistical analysis title	Injection site erythema
Comparison groups	Prevnam 13™ v V114

Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.003
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	7.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.8
upper limit	12.8

Statistical analysis title	Injection site induration
Comparison groups	V114 v Prevnar 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.882
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5
upper limit	4

Statistical analysis title	Injection site pain
Comparison groups	V114 v Prevnar 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.014
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.3
upper limit	11.3

Statistical analysis title	Injection site swelling
-----------------------------------	-------------------------

Comparison groups	V114 v Prevnar 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.051
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	8.9

Primary: Percentage of Participants with a Solicited Systemic Adverse Event

End point title	Percentage of Participants with a Solicited Systemic Adverse Event
End point description:	
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs included decreased appetite, irritability, somnolence (drowsiness), and urticaria (hives or welts). The analysis population for this endpoint included all randomized participants who received at least 1 dose of study vaccination.	
End point type	Primary
End point timeframe:	
Up to Day 14 after each study vaccination	

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1965	433		
Units: Percentage of participants				
number (not applicable)				
Decreased appetite	41.6	36.0		
Irritability	74.9	69.3		
Somnolence	55.4	55.0		
Urticaria	5.9	6.7		

Statistical analyses

Statistical analysis title	Decreased appetite
Comparison groups	V114 v Prevnar 13™

Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.033
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	10.5

Statistical analysis title	Irritability
Comparison groups	V114 v Prevna 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.016
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	5.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	1
upper limit	10.5

Statistical analysis title	Somnolence
Comparison groups	V114 v Prevna 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.878
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	5.6

Statistical analysis title	Urticaria
-----------------------------------	-----------

Comparison groups	V114 v Prevnar 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.503
Method	Miettinen & Nurminen method
Parameter estimate	Difference in Percentage
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	1.5

Primary: Percentage of Participants with a Vaccine-related Serious Adverse Event

End point title	Percentage of Participants with a Vaccine-related Serious Adverse Event
-----------------	---

End point description:

A serious adverse event (SAE) is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs that were reported by the investigator to be at least possibly related to the study vaccination were summarized. The analysis population for this endpoint included all randomized participants who received at least 1 dose of study vaccination.

End point type	Primary
----------------	---------

End point timeframe:

Up to 6 months after Vaccination 4 (up to 19 months after Vaccination 1)

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1965	433		
Units: Percentage of participants				
number (not applicable)	0.1	0		

Statistical analyses

Statistical analysis title	Vaccine-related Serious Adverse Events
Comparison groups	V114 v Prevnar 13™
Number of subjects included in analysis	2398
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentage
Point estimate	0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.8
upper limit	0.4

Secondary: Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) at 30 Days after Vaccination 3 (Premature Infants only)

End point title	Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) at 30 Days after Vaccination 3 (Premature Infants only)
-----------------	--

End point description:

The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. This endpoint was part of a Premature Infant Immunogenicity Substudy. The analysis population included all randomized participants in the Premature Infant Immunogenicity Substudy who did not have protocol deviations that could have substantially affected the results of the immunogenicity analysis and who had sufficient data to perform the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

30 days after Vaccination 3 (approximately 5 months after Vaccination 1)

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	35		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Serotype 1 (n=38, 35)	1.15 (0.88 to 1.52)	1.61 (1.25 to 2.09)		
Serotype 3 (n=38, 35)	0.86 (0.65 to 1.13)	0.58 (0.45 to 0.76)		
Serotype 4 (n=38, 35)	1.41 (1.01 to 1.99)	1.27 (0.96 to 1.68)		
Serotype 5 (n=38, 35)	1.48 (1.04 to 2.10)	1.66 (1.09 to 2.53)		
Serotype 6A (n=38, 35)	1.37 (0.95 to 1.96)	3.19 (2.31 to 4.43)		
Serotype 6B (n=38, 35)	1.69 (1.15 to 2.48)	2.53 (1.64 to 3.89)		
Serotype 7F (n=38, 35)	1.95 (1.46 to 2.62)	2.92 (2.21 to 3.87)		
Serotype 9V (n=38, 35)	1.47 (1.08 to 2.00)	1.50 (1.07 to 2.12)		
Serotype 14 (n=38, 35)	4.38 (3.18 to 6.03)	6.52 (4.35 to 9.77)		
Serotype 18C (n=38, 35)	1.46 (1.08 to 1.96)	1.54 (1.16 to 2.04)		
Serotype 19A (n=38, 35)	1.63 (1.25 to 2.13)	3.00 (2.18 to 4.11)		
Serotype 19F (n=38, 35)	2.03 (1.53 to 2.68)	2.78 (2.17 to 3.58)		

Serotype 23F (n=38, 35)	1.17 (0.81 to 1.70)	1.18 (0.82 to 1.68)		
Serotype 22F (n=38, 35)	4.33 (3.18 to 5.90)	0.05 (0.03 to 0.07)		
Serotype 33F (n=38, 35)	1.58 (0.93 to 2.69)	0.05 (0.04 to 0.08)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMC of Serotype-specific IgG before Vaccination 4 (Premature Infants only)

End point title	GMC of Serotype-specific IgG before Vaccination 4 (Premature Infants only)
-----------------	--

End point description:

The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. This endpoint was part of a Premature Infant Immunogenicity Substudy. The analysis population included all randomized participants in the Premature Infant Immunogenicity Substudy who did not have protocol deviations that could have substantially affected the results of the immunogenicity analysis and who had sufficient data to perform the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Before Vaccination 4 (10-13 months after Vaccination 1)

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	40		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Serotype 1 (n=38, 40)	0.30 (0.24 to 0.38)	0.47 (0.38 to 0.59)		
Serotype 3 (n=38, 40)	0.22 (0.16 to 0.29)	0.13 (0.10 to 0.17)		
Serotype 4 (n=38, 40)	0.24 (0.19 to 0.31)	0.31 (0.24 to 0.38)		
Serotype 5 (n=38, 40)	0.77 (0.60 to 1.01)	0.89 (0.65 to 1.22)		
Serotype 6A (n=38, 40)	0.32 (0.24 to 0.43)	0.72 (0.52 to 0.99)		
Serotype 6B (n=38, 40)	0.59 (0.47 to 0.75)	0.61 (0.43 to 0.87)		
Serotype 7F (n=38, 40)	0.57 (0.44 to 0.73)	0.95 (0.74 to 1.21)		
Serotype 9V (n=38, 40)	0.40 (0.32 to 0.51)	0.46 (0.35 to 0.62)		
Serotype 14 (n=38, 40)	1.14 (0.84 to 1.54)	2.22 (1.73 to 2.84)		
Serotype 18C (n=38, 40)	0.35 (0.28 to 0.45)	0.36 (0.27 to 0.49)		

Serotype 19A (n=38, 40)	0.38 (0.29 to 0.51)	0.81 (0.52 to 1.24)		
Serotype 19F (n=38, 40)	0.41 (0.31 to 0.53)	0.69 (0.52 to 0.90)		
Serotype 23F (n=38, 40)	0.33 (0.24 to 0.45)	0.37 (0.26 to 0.52)		
Serotype 22F (n=38, 40)	1.24 (0.98 to 1.58)	0.05 (0.04 to 0.07)		
Serotype 33F (n=38, 40)	1.09 (0.82 to 1.45)	0.05 (0.04 to 0.07)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMC of Serotype-specific IgG at 30 Days after Vaccination 4 (Premature Infants only)

End point title	GMC of Serotype-specific IgG at 30 Days after Vaccination 4 (Premature Infants only)
-----------------	--

End point description:

The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. This endpoint was part of a Premature Infant Immunogenicity Substudy. The analysis population included all randomized participants in the Premature Infant Immunogenicity Substudy who did not have protocol deviations that could have substantially affected the results of the immunogenicity analysis and who had sufficient data to perform the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

30 days after Vaccination 4 (11-14 months after Vaccination 1)

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	39		
Units: µg/mL				
geometric mean (confidence interval 95%)				
Serotype 1 (n=34, 39)	1.56 (1.19 to 2.06)	1.96 (1.54 to 2.50)		
Serotype 3 (n=34, 39)	1.04 (0.80 to 1.36)	0.79 (0.60 to 1.06)		
Serotype 4 (n=34, 39)	1.55 (1.11 to 2.16)	1.61 (1.21 to 2.15)		
Serotype 5 (n=34, 39)	3.30 (2.34 to 4.65)	3.60 (2.53 to 5.13)		
Serotype 6A (n=34, 39)	4.18 (3.17 to 5.49)	6.38 (4.69 to 8.68)		
Serotype 6B (n=34, 39)	6.62 (5.24 to 8.37)	6.75 (4.43 to 10.28)		
Serotype 7F (n=34, 39)	4.01 (2.98 to 5.40)	5.10 (3.76 to 6.90)		
Serotype 9V (n=34, 39)	3.10 (2.36 to 4.08)	3.09 (2.31 to 4.12)		

Serotype 14 (n=34, 39)	5.40 (3.89 to 7.49)	7.15 (5.33 to 9.61)		
Serotype 18C (n=34, 39)	3.21 (2.32 to 4.45)	2.77 (1.99 to 3.85)		
Serotype 19A (n=34, 39)	4.96 (3.85 to 6.39)	6.47 (4.46 to 9.40)		
Serotype 19F (n=34, 39)	4.48 (3.51 to 5.73)	4.83 (3.66 to 6.38)		
Serotype 23F (n=34, 39)	2.38 (1.76 to 3.20)	3.04 (2.16 to 4.27)		
Serotype 22F (n=34, 38)	9.83 (7.47 to 12.92)	0.08 (0.07 to 0.11)		
Serotype 33F (n=34, 37)	5.46 (4.29 to 6.96)	0.10 (0.07 to 0.13)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Meeting Serotype-specific IgG Threshold of ≥ 0.35 $\mu\text{g/mL}$ 30 Days after Vaccination 3 (Premature Infants only)

End point title	Percentage of Participants Meeting Serotype-specific IgG Threshold of ≥ 0.35 $\mu\text{g/mL}$ 30 Days after Vaccination 3 (Premature Infants only)
-----------------	---

End point description:

The GMC of IgG serotype-specific antibodies to the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) included in V114 and Prevnar 13™ and 2 serotypes (22F and 33F) unique to V114 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. Immunoglobulin G for the 15 serotypes contained in V114 vaccine will be determined using a PnECL assay. This endpoint was part of a Premature Infant Immunogenicity Substudy. The analysis population included all randomized participants in the Premature Infant Immunogenicity Substudy who did not have protocol deviations that could have substantially affected the results of the immunogenicity analysis and who had sufficient data to perform the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

30 days after Vaccination 3 (approximately 5 months after Vaccination 1)

End point values	V114	Prevnar 13™		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	38	35		
Units: Percentage of participants				
number (confidence interval 95%)				
Serotype 1	97.4 (86.2 to 99.9)	97.1 (85.1 to 99.9)		
Serotype 3	89.5 (75.2 to 97.1)	74.3 (56.7 to 87.5)		
Serotype 4	94.7 (82.3 to 99.4)	97.1 (85.1 to 99.9)		
Serotype 5	97.4 (86.2 to 99.9)	88.6 (73.3 to 96.8)		
Serotype 6A	97.4 (86.2 to 99.9)	97.1 (85.1 to 99.9)		

Serotype 6B	92.1 (78.6 to 98.3)	94.3 (80.8 to 99.3)		
Serotype 7F	97.4 (86.2 to 99.9)	100 (90.0 to 100.0)		
Serotype 9V	97.4 (86.2 to 99.9)	94.3 (80.8 to 99.3)		
Serotype 14	100 (90.7 to 100.0)	97.1 (85.1 to 99.9)		
Serotype 18C	97.4 (86.2 to 99.9)	94.3 (80.8 to 99.3)		
Serotype 19A	94.7 (82.3 to 99.4)	97.1 (85.1 to 99.9)		
Serotype 19F	97.4 (86.2 to 99.9)	100 (90.0 to 100.0)		
Serotype 23F	89.5 (75.2 to 97.1)	94.3 (80.8 to 99.3)		
Serotype 22F	97.4 (86.2 to 99.9)	2.9 (0.1 to 14.9)		
Serotype 33F	86.8 (71.9 to 95.6)	2.9 (0.1 to 14.9)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Non-serious AEs: up to 14 days after each vaccination dose; serious AEs and deaths (all causes): up to 6 months after Vaccination 4 (up to 19 months after Vaccination 1)

Adverse event reporting additional description:

The safety analysis population included all randomized participants who received at least 1 dose of study vaccination.

The analysis population for number of deaths (all causes) included all randomized participants.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.1

Reporting groups

Reporting group title	V114
-----------------------	------

Reporting group description:

Participants received a single 0.5 mL IM injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).

Reporting group title	Prevnam 13™
-----------------------	-------------

Reporting group description:

Participants received a single 0.5 mL IM injection of Prevnam 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).

Serious adverse events	V114	Prevnam 13™	
Total subjects affected by serious adverse events			
subjects affected / exposed	192 / 1965 (9.77%)	45 / 433 (10.39%)	
number of deaths (all causes)	1	1	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatoblastoma			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration			

site conditions			
Pyrexia			
subjects affected / exposed	8 / 1965 (0.41%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	2 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Adenoidal hypertrophy			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apnoea			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal haemorrhage			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			

subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wheezing			
subjects affected / exposed	1 / 1965 (0.05%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental exposure to product			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone contusion			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burns second degree			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemical poisoning			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Concussion			
subjects affected / exposed	1 / 1965 (0.05%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fibula fracture			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	0 / 1965 (0.00%)	2 / 433 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Congenital absence of bile ducts			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cardio-respiratory arrest			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiomyopathy			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile convulsion			
subjects affected / exposed	4 / 1965 (0.20%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myoclonus			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paroxysmal choreoathetosis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Autoimmune haemolytic anaemia			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Gastrointestinal disorders			
Anal fistula			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	2 / 1965 (0.10%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea haemorrhagic			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			

subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 1965 (0.10%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Chronic recurrent multifocal osteomyelitis			

subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oligoarthritis			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Arthritis bacterial			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis			
subjects affected / exposed	27 / 1965 (1.37%)	7 / 433 (1.62%)	
occurrences causally related to treatment / all	0 / 29	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	8 / 1965 (0.41%)	2 / 433 (0.46%)	
occurrences causally related to treatment / all	0 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			

subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coxsackie viral infection			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Croup infectious			
subjects affected / exposed	2 / 1965 (0.10%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	3 / 1965 (0.15%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovirus infection			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia pyelonephritis			
subjects affected / exposed	8 / 1965 (0.41%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	6 / 1965 (0.31%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exanthema subitum			

subjects affected / exposed	7 / 1965 (0.36%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	15 / 1965 (0.76%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 17	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis adenovirus			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	2 / 1965 (0.10%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis salmonella			
subjects affected / exposed	4 / 1965 (0.20%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis shigella			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			

subjects affected / exposed	5 / 1965 (0.25%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand-foot-and-mouth disease			
subjects affected / exposed	3 / 1965 (0.15%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpangina			
subjects affected / exposed	3 / 1965 (0.15%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	4 / 1965 (0.20%)	3 / 433 (0.69%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metapneumovirus infection			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	3 / 1965 (0.15%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral herpes			

subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pertussis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	12 / 1965 (0.61%)	4 / 433 (0.92%)	
occurrences causally related to treatment / all	0 / 13	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			
subjects affected / exposed	2 / 1965 (0.10%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia parainfluenzae viral			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia respiratory syncytial viral			

subjects affected / exposed	5 / 1965 (0.25%)	2 / 433 (0.46%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	7 / 1965 (0.36%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	9 / 1965 (0.46%)	4 / 433 (0.92%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus bronchitis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	2 / 1965 (0.10%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			

subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	3 / 1965 (0.15%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheitis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	5 / 1965 (0.25%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	2 / 1965 (0.10%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			

subjects affected / exposed	4 / 1965 (0.20%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral pharyngitis			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 1965 (0.05%)	0 / 433 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	0 / 1965 (0.00%)	1 / 433 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	V114	Pprevnar 13™	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1807 / 1965 (91.96%)	395 / 433 (91.22%)	
Nervous system disorders			
Somnolence			
subjects affected / exposed	1088 / 1965 (55.37%)	238 / 433 (54.97%)	
occurrences (all)	2696	590	
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	863 / 1965 (43.92%)	156 / 433 (36.03%)	
occurrences (all)	1528	272	

Injection site induration subjects affected / exposed occurrences (all)	497 / 1965 (25.29%) 885	111 / 433 (25.64%) 205	
Injection site pain subjects affected / exposed occurrences (all)	843 / 1965 (42.90%) 1580	158 / 433 (36.49%) 288	
Injection site swelling subjects affected / exposed occurrences (all)	549 / 1965 (27.94%) 929	101 / 433 (23.33%) 163	
Pyrexia subjects affected / exposed occurrences (all)	775 / 1965 (39.44%) 1533	176 / 433 (40.65%) 329	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	 188 / 1965 (9.57%) 235 116 / 1965 (5.90%) 135	 40 / 433 (9.24%) 49 19 / 433 (4.39%) 20	
Skin and subcutaneous tissue disorders Urticaria subjects affected / exposed occurrences (all)	 115 / 1965 (5.85%) 139	 29 / 433 (6.70%) 40	
Psychiatric disorders Irritability subjects affected / exposed occurrences (all)	 1472 / 1965 (74.91%) 5402	 300 / 433 (69.28%) 1053	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all) Upper respiratory tract infection subjects affected / exposed occurrences (all)	 158 / 1965 (8.04%) 182 129 / 1965 (6.56%) 139	 37 / 433 (8.55%) 41 30 / 433 (6.93%) 32	
Metabolism and nutrition disorders			

Decreased appetite subjects affected / exposed	817 / 1965 (41.58%)	156 / 433 (36.03%)	
occurrences (all)	1664	302	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 March 2019	Amendment 1: The main purpose for this protocol amendment was to add opsonophagocytic activity (OPA) testing to the Premature Infant Immunogenicity Substudy.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported